Distinguished in Pulmonary Fibrosis

Dr. Rajeev C. Saggar

Pulmonary Medicine
500 W Thomas Rd, Suite 500, 
Phoenix, AZ 
Distinguished in Pulmonary Fibrosis
500 W Thomas Rd, Suite 500, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajeev Saggar is a Pulmonary Medicine provider in Phoenix, Arizona. Dr. Saggar is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Pulmonary Hypertension, Acute Interstitial Pneumonia, Pulmonary Fibrosis, Interstitial Lung Disease, and Lung Transplant.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles and participated in 3 clinical trials in the study of Pulmonary Fibrosis.

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in AZ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

500 W Thomas Rd, Suite 500, Phoenix, AZ 85013

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Prospective Single Center Randomized Trial of Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation.
A Prospective Single Center Randomized Trial of Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation.
Enrollment Status: Withdrawn
Publish Date: September 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study
Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study
Enrollment Status: Withdrawn
Publish Date: March 06, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

50 Total Publications

Correction to: BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.
Correction to: BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.
Journal: Circulation
Published: April 28, 2025
Similar Doctors
Elite in Pulmonary Fibrosis
Dr. Rajat Walia
Pulmonary Medicine | Intensive Care Medicine
Elite in Pulmonary Fibrosis
Dr. Rajat Walia
Pulmonary Medicine | Intensive Care Medicine

Sjhmc Physician Services

500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
 (0.1 miles away)
602-406-6017
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rajat Walia is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Phoenix, Arizona. Dr. Walia is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Acute Interstitial Pneumonia, Lung Transplant, and Tissue Biopsy. Dr. Walia is currently accepting new patients.

Distinguished in Pulmonary Fibrosis
Dr. Dana H. Reihman
Pulmonary Medicine
Distinguished in Pulmonary Fibrosis
Dr. Dana H. Reihman
Pulmonary Medicine

Desert Center For Allergy And Chest Diseases

6970 E Chauncey Ln, Suite 100, 
Phoenix, AZ 
 (14.7 miles away)
602-788-7211
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dana Reihman is a Pulmonary Medicine provider in Phoenix, Arizona. Dr. Reihman is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Gastrostomy. Dr. Reihman is currently accepting new patients.

Lewis J. Wesselius
Distinguished in Pulmonary Fibrosis
Dr. Lewis J. Wesselius
Pulmonary Medicine
Distinguished in Pulmonary Fibrosis
Dr. Lewis J. Wesselius
Pulmonary Medicine
13400 E Shea Blvd, 
Scottsdale, AZ 
 (17.9 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lewis Wesselius is a Pulmonary Medicine provider in Scottsdale, Arizona. Dr. Wesselius is rated as a Distinguished provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Pneumonia, Lung Metastases, Acute Interstitial Pneumonia, and Bronchiectasis. Dr. Wesselius is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saggar's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile